EMA Recommends Granting Marketing Authorisation for Generic Arsenic Trioxide

Arsenic trioxide Mylan is a generic of Trisenox, which has been authorised in the EU since 2002.
26 Feb 2020
Anticancer agents & Biologic therapy;  Haematologic malignancies

On 30 January 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Arsenic trioxide Mylan, intended for the treatment of acute promyelocytic leukaemia (APL).  

The applicant for this medicinal product is Mylan Ireland Limited. 

Arsenic trioxide Mylan will be available as 1 mg/ml concentrate for solution for infusion. The active substance of Arsenic trioxide Mylan is arsenic trioxide, an antineoplastic agent (ATC code: L01XX27) that causes fragmentation, damage or degradation of deoxyribonucleic acid and the fusion protein pro-myelocytic leukaemia/retinoic acid receptor-alpha (PML/RAR alpha) in promyelocytic leukaemia cells. The mechanism of action of arsenic trioxide is not completely understood. 

Arsenic trioxide Mylan is a generic of Trisenox, which has been authorised in the EU since 5 March 2002. Since Arsenic trioxide Mylan is administered intravenously and is 100% bioavailable, a bioequivalence study versus the reference product Trisenox was not required. 

Arsenic trioxide Mylan is indicated for induction of remission, and consolidation in adult patients with: 

  • Newly diagnosed lowtointermediate risk APL (white blood cell count, ≤ 10 x 103/μl) in combination with alltransretinoic acid  

  • Relapsed/refractory APL (previous treatment should have included a retinoid and chemotherapy) 

characterised by the presence of the t(15;17) translocation and/or the presence of the PML/RARalpha gene. 

The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined. 

It is proposed that Arsenic trioxide Mylan be prescribed by physicians experienced in the treatment of acute leukaemias. 

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings